SPRY NASDAQ
ARS Pharmaceuticals, Inc.
1W: -0.2%
1M: -30.1%
3M: -51.1%
YTD: -64.6%
1Y: -59.7%
3Y: +11.8%
5Y: -61.6%
$4.07
-0.05 (-1.21%)
Weekly Expected Move ±8.1%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (63)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Small-cap stocks with weak momentum grades and steep YTD losses
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Pentair plc (PNR), Datavault AI Inc. (DVLT), and ARS Pharmaceuticals, Inc. (SPRY) Announced by Holzer & Holzer, LLC
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $28.20
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 2026
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
ARS Pharmaceuticals appoints new CEO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
Biggest stock movers Thursday: AI chip stocks, WEN, SPRY, and more
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program
ARS Pharma (SPRY) Q4 2025 Earnings Transcript
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
Cronos Group (CRON) Q1 Earnings Meet Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
Top and lowest-rated small-cap stocks heading into earnings
Q1 Earnings Forecast for SPRY Issued By Northland Securities
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $28.25
Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY
ARS Pharma gains FDA clearance to remove age restriction from neffy
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026
ARS Pharmaceuticals: Q4 Earnings Insights
Earnings Scheduled For March 9, 2026
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
Here are the major earnings before the open Monday
Exploring ARS Pharmaceuticals's Earnings Expectations
Canadian Natural to Report Q4 Earnings: What's in the Offing?
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to
Campbell & CO Investment Adviser LLC Takes Position in ARS Pharmaceuticals, Inc. $SPRY
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
FAS Wealth Partners Inc. Buys 51,460 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of “Moderate Buy” by Brokerages
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
53,341 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Permanent Capital Management LP
Ardsley Advisory Partners LP Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of “Moderate Buy” from Analysts
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference